PDCD1 and non-small cell lung carcinoma: ICIs targeting programmed cell death protein 1 (PD-1) or its ligand PD-L1 have demonstrated improved clinical efficacy in both second-line and first-line treatment of advanced NSCLC when compared to conventional chemotherapy (Sui et al., 2018).